Zymeworks (ZYME) Assets Average (2022 - 2026)
Zymeworks (ZYME) posted Assets Average of $412.4 million for Q1 2026, up 10.88% sequentially from $371.9 million in Q4 2025, and down 7.19% YoY from $444.3 million in Q1 2025.
Analysis
Zymeworks (ZYME) Assets Average (2022 - 2026) Analysis & Trends
Zymeworks has reported Assets Average for 5 years, with the latest figure at $412.4 million in Q1 2026.
- Quarterly Assets Average fell 7.19% year-over-year to $412.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $412.4 million (down 7.19% YoY) and the FY2025 annual result came in at $404.8 million, down 22.45% from the prior year.
- Assets Average advanced to $412.4 million in Q1 2026 per ZYME's latest filing, from $371.9 million in the prior quarter.
- Over five years, Assets Average peaked at $624.7 million in Q1 2023 and troughed at $371.9 million in Q4 2025.
- A 5-year average of $498.2 million and a median of $488.3 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average climbed 19.84% in 2023, then dropped 22.02% in 2025.
- Over 5 years, Assets Average stood at $474.5 million in 2022, then gained by 19.84% to $568.6 million in 2023, then retreated by 16.44% to $475.1 million in 2024, then slipped by 21.73% to $371.9 million in 2025, then advanced by 10.88% to $412.4 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $412.4 million, $371.9 million, and $402.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 437.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 437.59 Mn |
| Mar 31, 2026 | 412.37 Mn |
| Dec 31, 2025 | 371.90 Mn |
| Sep 30, 2025 | 402.83 Mn |
| Jun 30, 2025 | 416.95 Mn |
| Mar 31, 2025 | 444.31 Mn |
| Dec 31, 2024 | 475.12 Mn |
| Sep 30, 2024 | 501.39 Mn |
| Jun 30, 2024 | 534.69 Mn |
| Mar 31, 2024 | 567.32 Mn |
| Dec 31, 2023 | 568.62 Mn |
| Sep 30, 2023 | 579.21 Mn |
| Jun 30, 2023 | 601.40 Mn |
| Mar 31, 2023 | 624.73 Mn |
| Dec 31, 2022 | 474.49 Mn |